city New Delhi India covid-19 vaccine Volunteers city New Delhi India

Bharat Biotech enrolment in Covaxin phase 3 trial crosses halfway mark of 13,000

Reading now: 365
www.livemint.com

NEW DELHI : Bharat Biotech International Ltd’s enrolment of participants in its phase 3 efficacy trial of Covaxin has crossed the halfway mark of 13,000 participants in just about a month after starting its trial, the company said on Tuesday.The Phase 3 human clinical trials of Covaxin began in mid-November, and the company plans to recruit 26,000 volunteers at more than two dozen sites across India for it.

So far, this is India’s first and only Phase 3 efficacy study for a covid-19 vaccine, and the largest phase 3 efficacy trial ever conducted for any vaccine in India.Also Read | Dark underbelly of India Inc’s shop floorsThe company, however, refused to divulge details on how many of the 13,000 participants have received two doses of the.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA